STOCK TITAN

Cencora Inc. - COR STOCK NEWS

Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.

Cencora Inc. (NYSE: COR) operates at the core of global healthcare distribution, connecting pharmaceutical manufacturers with providers worldwide. This page aggregates official announcements and verified news covering strategic developments across its pharmaceutical distribution networks, manufacturer partnerships, and specialty logistics operations.

Investors and industry professionals will find comprehensive coverage of earnings updates, regulatory milestones, supply chain innovations, and strategic acquisitions. Track COR’s progress in enhancing healthcare access through its commercialization services for drug manufacturers and temperature-controlled logistics via World Courier.

Key updates include expansions in animal health distribution through MWI Animal Health, partnerships with healthcare providers, and operational developments following the Alliance Healthcare integration. All content is curated to support analysis of COR’s role in the evolving pharmaceutical wholesale sector.

Bookmark this page for streamlined access to Cencora’s latest press releases and market-moving updates, essential for monitoring one of healthcare’s critical infrastructure providers.

Rhea-AI Summary

Cencora (NYSE: COR) has announced a significant share repurchase agreement with Walgreens Boots Alliance Holdings, totaling approximately $400 million. This transaction is part of a broader strategy, with Cencora completing around $550 million in share repurchases in May 2024 alone. Additionally, Cencora has raised its fiscal year 2024 adjusted diluted earnings per share (EPS) guidance to a range of $13.35 to $13.55, up from the previous $13.30 to $13.50. The improved EPS forecast is attributed to a reduced share count, although it is partially offset by increased net interest expenses due to lower investment balances following the repurchases. Cencora, a global pharmaceutical solutions leader, is recognized on the Fortune 500 and Global Fortune 500 lists, with annual revenues exceeding $250 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
buyback earnings
-
Rhea-AI Summary

Walgreens Boots Alliance (WBA) has sold approximately $400 million worth of Cencora (COR) shares through a stock repurchase agreement, decreasing its ownership from 13% to 12%.

The proceeds will be used mainly for debt reduction and general corporate purposes, supporting WBA's strategy to enhance its health services rooted in retail pharmacy.

The sale does not affect the ongoing collaboration or long-term strategic partnership between the companies. Ornella Barra, COO International of WBA, will continue to serve on Cencora's Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary

Cencora, Inc. (NYSE: COR) reported a revenue of $68.4 billion for the second quarter, marking a 7.8% increase year-over-year. The GAAP diluted EPS stood at $2.09, with adjusted diluted EPS at $3.80. The company raised its adjusted diluted EPS guidance range to $13.30 to $13.50 for fiscal 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) is set to release its Second Quarter Fiscal 2024 results on May 1, 2024. The company will host a conference call featuring key executives to discuss the results. Participants can join the call via webcast or telephone, with replays available for both options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces CEO Steven H. Collis transitioning to Executive Chair, COO Robert P. Mauch to become President and CEO effective October 1, 2024. Collis praised for 30-year career, phenomenal financial growth, global expansion, and strategic partnerships. Mauch, with extensive experience, set to continue company's pharmaceutical-centric strategy. Company reaffirms fiscal year 2024 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced a $50 million share repurchase agreement with Walgreens Boots Alliance Holdings LLC, in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933. The company intends to repurchase shares at the price per share equal to the price in the Rule 144 sale, under its share repurchase program. The repurchased shares will be held in treasury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
buyback
Rhea-AI Summary
Walgreens Boots Alliance (WBA) has sold shares of Cencora, Inc. (COR) for $992 million, with $942 million sold pursuant to Rule 144 and a concurrent share repurchase by Cencora of approximately $50 million. The proceeds will be used for debt paydown and general corporate purposes, with no impact on the ongoing collaboration and long-term strategic partnership between the two companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (COR) has successfully closed a public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034. The company filed a registration statement with the SEC and intends to use the net proceeds to redeem its 3.400% Senior Notes due May 15, 2024, with any remaining funds for general corporate purposes. The joint book-running managers for the offering were BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced the pricing of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 in a public offering. The company plans to use the net proceeds to redeem all of its 3.400% Senior Notes due May 15, 2024, with any remaining net proceeds for general corporate purposes. The joint book-running managers for the offering are BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The offering is expected to close on February 7, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 15.0% increase in revenue to $72.3 billion for the first quarter of fiscal year 2024. Adjusted diluted EPS also increased by 21.0% to $3.28. The company raised its adjusted diluted EPS guidance range to $13.25 to $13.50 for fiscal 2024. U.S. Healthcare Solutions revenue grew by 15.9%, and International Healthcare Solutions revenue grew by 6.9% in the first quarter. The company's fiscal year 2024 expectations include revenue growth of 10-12% and adjusted diluted earnings per share of $13.25 to $13.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Cencora Inc.

NYSE:COR

COR Rankings

COR Stock Data

55.55B
182.62M
6.85%
92.69%
3.58%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
CONSHOHOCKEN